Inferring ECOG performance status (PS) using large language models in patients with advanced prostate cancer.
Abstract
136 Background: The ECOG performance status (PS) is a critical measure for evaluating functional capacity and determining clinical trial eligibility in patients with advanced prostate cancer. We aim to assess the capability of large language models (LLMs) to accurately infer ECOG PS from unstructured oncology notes. Methods: This retrospective study included patients with metastatic castration-resistant prostate cancer (mCRPC) receiving Lutetium-177–PSMA-617 ( 177 Lu) at the Mayo Clinic (2022-2023). Baseline ECOG PS scores were manually curated by a trained clinician from clinical notes recorded within four weeks prior to 177 Lu initiation. Structured zero-shot prompts were then used to prompt GPT-4 to infer ECOG PS scores from unstructured oncology notes. Total dataset was randomly sampled to prompt development (20%) and held-out test set (80%). Three experimental setups were employed to assess model performance: (i) utilizing unmasked clinical notes, (ii) clinical notes with only numerical ECOG PS scores masked while retaining narrative descriptive/assessment by oncologist of ECOG score, and (iii) clinical notes with both numerical scores and narrative ECOG descriptors masked. Final performance was assessed using evaluation metrics (precision, recall, F1 score) on the held-out test set. Results: A total of 240 patients (n: 50 prompt development; n: 190 test set) were included in the analysis. The median age was 70 (IQR: 66-76); a majority of patients were White (n: 229; 95%) and non-Hispanic (n: 233; 97%). The most prevalent ECOG PS score was 0 (n: 140; 58%), followed by 1 (n: 88; 37%), and 2 (n: 12; 5%). The performance was numerically higher when using unmasked notes (weighted average precision: 0.89; recall: 0.89; F1: 0.89), compared to using notes with masked scores only (weighted average precision: 0.76; recall: 0.79; F1: 0.75) and notes with both scores and narrative masked (weighted average precision: 0.57; recall: 0.53; F1: 0.48). Metrics by each ECOG PS score is outlined (Table). Conclusions: Large language models demonstrate significant potential in precisely extracting ECOG performance status from unstructured oncology notes, offering valuable support for treatment decision-making and clinical trial enrollment. However, model performance declines as reliance on implicit reporting within clinical notes increases. Future efforts focusing on prediction of ECOG using a series of notes over time will be the next step. ECOG Unmasked oncology notes ECOG Score masked only ECOG Score + ECOG narrative marked Precision Recall F1 Score Precision Recall F1 Score Precision Recall F1 Score 0 0.89 0.92 0.91 0.75 0.93 0.83 0.59 0.74 0.66 1 0.88 0.86 0.87 0.76 0.74 0.75 0.19 0.47 0.27 2 1.00 0.82 0.90 0.78 0.33 0.47 0.78 0.16 0.26
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (16)
Ammad Raina
Midwestern University, AZCOM, Glendale, AZ
Miguel Muniz
Department of Medical Oncology, Mayo Clinic Rochester, Rochester, MN
Muhammad Umair Anjum
The Wright Center for GME, Scranton, Pennsylvania, United States
Umair Ayub
1Mayo Clinic, Division of Hematology/Oncology, Department of Internal Medicine, Phoenix, United States
Syed Arsalan Ahmed Naqvi
Mayo Clinic, Phoenix, AZ
Salman Ayub Jajja
NYMC-LANDMARK MEDICAL CENTER, RI, Woonsocket, Rhode Island, United States
Ji-Eun Yum
Mayo Clinic Alix School of Medicine, Scottsdale, AZ
Ben Zhou
CAS Key Laboratory of Nutrition, Metabolism and Food Safety Shanghai Institute of Nutrition and Health University of Chinese Academy of Sciences Chinese Academy of Sciences Shanghai 200031 China
Nathan Y Yu
Mayo Clinic in Arizona, Phoenix, AZ
Haidar Abdul-Muhsin
Mayo Clinic Arizona, Phoenix, AZ
Alton Oliver Sartor
LCMC Health, New Orleans, LA
Jacob Orme
Department of Medical Oncology, Mayo Clinic Rochester, Rochester, MN
Parminder Singh
Department of Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ
Yousef Zakharia
Division of Hematology and Medical Oncology, Department of Internal Medicine Mayo Clinic Phoenix Arizona USA
Daniel S Childs
Division of Medical Oncology, Mayo Clinic Rochester, Rochester, MN
Irbaz Bin Riaz
Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA